Nuvectis Pharma Q2 EPS $(0.38) Misses $(0.29) Estimate
Portfolio Pulse from Benzinga Newsdesk
Nuvectis Pharma reported Q2 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.29) by 31.03%. This represents a 35.71% increase in losses compared to the same period last year.
August 09, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nuvectis Pharma's Q2 earnings were worse than expected, with losses per share of $(0.38), missing estimates by 31.03%. This is a significant increase in losses compared to the same period last year.
Nuvectis Pharma's Q2 earnings were significantly worse than expected, with losses per share missing estimates by 31.03%. This is a significant increase in losses compared to the same period last year, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100